NCT04790513View on ClinicalTrials.gov

Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

April 22, 2021

Primary Completion Date

September 30, 2022

Study Completion Date

December 31, 2022

Conditions
HypercholesterolemiaCardiovascular Diseases
Interventions
BIOLOGICAL

lerodalcibep

anti-PCSK9 small binding protein

BIOLOGICAL

evolocumab

monoclonal antibody to PCSK9

BIOLOGICAL

alirocumab

monoclonal antibody to PCSK9

Trial Locations (3)

45219

Sterling Research Group, Cincinnati

The Lindner Research Center, Cincinnati

45227

Metabolic & Atherosclerosis Research Center (MARC), Cincinnati

Sponsors
All Listed Sponsors
lead

LIB Therapeutics LLC

INDUSTRY